ACT Brief: RWD Integration Accelerates, FDA Advances Ultra-Rare Therapies, and Collaboration Shapes the Next Decade

In today’s ACT Brief, we examine how the Verana Health-COTA merger is evolving real-world data use, the FDA’s new framework for individualized ultra-rare disease therapies, and what a decade of cross-industry collaboration reveals about the future of clinical development.